智通财经APP讯，百奥赛图-B(02315)发布2025年度业绩预告，经公司财务部门初步测算，预计本集团2025年年度实现营业收入人民币13.69亿元至人民币13.89亿元，与上年同期相比，将增加人民币3.88亿元至人民币4.08亿元，同比增加39.61%至41.65%。预计本集团2025年年度实现归属于母公司所有者的净利润人民币1.62亿元至人民币1.82亿元，与上年同期相比，将增加人民币1.29亿元到人民币1.49亿元，同比增加384.26%到443.88%。预计本集团2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润人民币1.05亿元到人民币1.25亿元，与上年同期相比，将增加人民币8195.13万元到人民币1.02亿元，同比增加356.81%到443.88%。
公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.